Zevra Therapeutics
ZVRA
Insider trades and stock quote 2024-2026
All insider trades at Zevra Therapeutics
| Date |
Type |
Insider |
Position |
Ø-Price |
Volume |
|
8/10/2026
|
Sell |
Watton, Corey Michael |
Director |
$11.3 |
$138,377 |
|
6/22/2026
|
Sell |
Thompson, Rahsaan |
Chief Legal & Compliance |
$12.7 |
$438,304 |
|
5/11/2026
|
Sell |
Thompson, Rahsaan |
Chief Legal & Compliance |
$11.3 |
$20,272 |
|
2/9/2026
|
Sell |
Mcfarlane, Neil F. |
President and CEO |
$8.6 |
$125,186 |
|
2/3/2026
|
Sell |
Sangiovanni, Timothy J. |
SVP, Finance & Corp Controller |
$9.2 |
$27,548 |
|
2/3/2026
|
Sell |
Schafer, Joshua |
CCO |
$9.2 |
$96,500 |
|
2/2/2026
|
Sell |
Mcfarlane, Neil F. |
President and CEO |
$9.4 |
$853,425 |
|
1/30/2026
|
Sell |
Sangiovanni, Timothy J. |
SVP, Finance & Corp Controller |
$8.8 |
$15,442 |
|
1/30/2026
|
Sell |
Thompson, Rahsaan |
Chief Legal & Compliance |
$8.8 |
$36,010 |
|
1/30/2026
|
Sell |
Quartel, Adrian W. |
Chief Medical Officer |
$8.8 |
$40,036 |
|
1/30/2026
|
Sell |
Schafer, Joshua |
CCO |
$8.8 |
$29,800 |
|
10/10/2025
|
Sell |
Mcfarlane, Neil F. |
President and CEO |
$10.8 |
$210,908 |
|
9/12/2025
|
Buy |
Seymour, Tamara A. |
Director |
$7.8 |
$24,718 |
|
9/12/2025
|
Buy |
Shih, Alvin |
Director |
$7.9 |
$157,800 |
|
8/19/2025
|
Buy |
Bode, John B. |
Director |
$9.2 |
$45,825 |
|
6/26/2025
|
Sell |
Thompson, Rahsaan |
Chief Legal & Compliance |
$9.2 |
$221,004 |
|
3/28/2025
|
Buy |
Watton, Corey Michael |
Director |
$7.8 |
$2,352 |
|
3/19/2025
|
Buy |
Bode, John B. |
Director |
$8.0 |
$79,624 |
|
2/14/2025
|
Sell |
Mcfarlane, Neil F. |
President and CEO |
$8.1 |
$245,962 |
|
2/13/2025
|
Sell |
Mcfarlane, Neil F. |
President and CEO |
$7.9 |
$481,428 |
|
2/13/2025
|
Sell |
Clifton, R. Laduane |
CFO & Treasurer |
$7.9 |
$86,471 |
|
2/13/2025
|
Sell |
Schafer, Joshua |
CCO & EVP, Bus. Development |
$7.9 |
$82,527 |
|
2/13/2025
|
Sell |
Sangiovanni, Timothy J. |
SVP, Finance & Corp Controller |
$7.9 |
$23,588 |
|
10/11/2024
|
Buy |
Watton, Corey Michael |
Director |
$7.9 |
$3,958 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)
Free Updates via Email
Please confirm your email address